Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Giles W. Robinson,Amar J. Gajjar,Karen Gauvain,Ellen M. Basu,Margaret E. Macy,Luke Maese,Amit J. Sabnis,Jennifer Foster,Suzanne Shusterman,Janet M. Yoon,Brian Weiss,Mohamed S. AbdelBaki,Mufiza Farid-Kapadia,Georgina Meneses-Lorente,Alison Cardenas,Katherine E. Hutchinson,Guillaume Bergthold,Edna Chow Maneval,Elizabeth Fox,Ami V. Desai

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

2019

10009Background: Entrectinib is a CNS-penetrant oral inhibitor of TrkA/B/C, ROS1 and ALK tyrosine kinases. We report the efficacy of entrectinib in children with recurrent/refractory solid or CNS t...

Keywords:

Refractory
CNS TUMORS
Central nervous system
Entrectinib
Pathology
Medicine
Tyrosine kinase
Cancer research
Tropomyosin receptor kinase A
ROS1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations